



Future Targeted Healthcare Manufacturing Hub T-Cell Processing Specialist Working Group

Agenda

Thursday 19 September 2019, 13.00-17:00, UCL Bloomsbury Campus

1:00 Arrival and Refreshments

1:20 Roundtable Introductions

1:30 Update on Hub Cell and Gene Therapy Activity and Strategy

Qasim Rafiq, UCL

1:40 Hub research plans and progress in T-Cell Processing, Modelling, Supply Chain and Regulation

Maryam Shariatzadeh: Mechanistic Modelling for T-cell Therapy Manufacture

Igor Andreyev: Development of Analytical and Microfluidic Applications for Cell Therapies

Shimaz Hashimdeen: Investigation of key culture parameters for T-cell production

Carlos Villalobos: Outlook for CAR T-cell Process Optimization and Control Using Multivariate Statistics

Maria Papathanasiou: Analysis of the Current and Future CAR T Cell Supply Chain

Giovanni de Grandis: ATMP Regulations and Interactions with Regulators: Key Issues

3:10 Break and Refreshments

3:30 Hub Aligned PDRA and PhD Project Presentations

Elena Costariol: Process Development and Manufacture of Primary Human T-cells and CAR-T Cells in Automated Stirred-tank Bioreactors

Marco Rotondi: Process Intensification Methods for T-cell Manufacture in Stirred-tank Bioreactors

Theano Panagopoulou: Standardising Viral Vector Production Using Chemically-defined Media

Vaques George: Validating the Serum-Free Manufacture of Blood-Derived $\gamma\delta$ T-cells Towards Clinical Applications

4.30 Roundtable Discussions to Scope Future Direction of Hub Research

1. What are the key emerging areas or opportunities within the cell and gene therapy sector?
2. What are the manufacturing and process development bottlenecks for cell and gene therapies?
3. Within the Targeted Healthcare remit, what relevant CGT research questions should be explored by Hub research?

5.00 Feedback and Round-up

Opportunities for collaboration

Focus for future workshops

5.15 Close